Equine herpesvirus 4 (EHV-4) is a highly prevalent pathogen within the equine industry, primarily causing mild respiratory disease in weaned foals and young horses. While often less clinically severe than its counterpart EHV-1, EHV-4 remains a significant concern due to its extremely high transmissibility and capacity to establish lifelong latent infections. Understanding the nuances of this virus is critical for implementing effective biosecurity and management strategies on any equine property.
Virology and Pathogenesis
Belonging to the family *Herpesviridae*, EHV-4 specifically targets epithelial cells lining the upper respiratory tract following aerosol transmission. The virus replicates within these cells, causing inflammation and damage that leads to the characteristic signs of the common cold. After the initial infection is cleared, the virus travels along sensory nerves to establish latency in the trigeminal ganglion, where it can persist for the life of the animal. Reactivation of the latent virus, often triggered by stress such as transport or intense training, results in periods of viral shedding without overt disease, acting as a constant source of infection for susceptible horses.
Clinical Signs and Diagnosis
The clinical presentation of EHV-4 infection is typically mild, primarily affecting the respiratory system. Key signs include a clear or slightly purulent nasal discharge, a low-grade fever, and a dry, hacking cough. While pneumonia is rare in adult horses, very young foals are at a higher risk of developing more severe respiratory distress. Diagnosis is usually based on clinical signs in a young, coughing horse within a group setting, but definitive confirmation requires laboratory testing. This involves polymerase chain reaction (PCR) assays on nasal swabs or washes to detect viral DNA, distinguishing it from other respiratory pathogens.
Differentiating EHV-4 from EHV-1
Key Differences in Pathogenicity
A crucial aspect of managing equine herpesviruses is understanding the distinct threats posed by EHV-4 and EHV-1. The primary difference lies in their pathogenic potential: EHV-1 is notorious for causing abortion storms in pregnant mares, neonatal foal mortality, and life-threatening neurological disease (equine herpesvirus myeloencephalopathy). In contrast, EHV-4 is primarily a respiratory pathogen. It rarely causes abortion or neurological issues, making it a significant but generally less severe concern compared to the systemic and reproductive havoc caused by EHV-1.
Impact on the Equine Industry
The economic impact of EHV-4 is largely indirect but substantial. While the acute illness results in veterinary costs and lost training time, the major consequence is the quarantine and isolation required during outbreaks. Facilities such as training barns, boarding stables, and show venues must implement strict protocols to prevent the spread, which can disrupt schedules and revenue. Furthermore, the virus's latency complicates breeding programs, as seropositive mares may need additional monitoring to ensure they do not pose a risk to foals, even if they show no active respiratory signs.
Prevention and Biosecurity Measures
Preventing the introduction and spread of EHV-4 relies heavily on robust biosecurity. New arrivals should be quarantined for a minimum of 21 days and monitored closely before integrating them with the resident herd. Hygiene is paramount; handlers should change clothing and disinfect equipment between groups of horses. Vaccination plays a supportive role in management; while the available vaccines are not 100% effective at preventing infection, they are highly effective at reducing the severity and duration of respiratory signs. Regular vaccination of young horses and performance animals is a standard practice to mitigate outbreaks.
